Vevye (Cyclosporine) Patent Expiration, LOE Window & CMS Spending

Vevye (Cyclosporine) by Harrow Eye: FDA Orange Book LOE 2042-04-01, 16 AB generics, $16.2M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorHarrow Eye
FDA Application & PathwayN217469 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2042-04-01
Orange Book Patents (*PED Extensions)5 patents (0 *PED)
Active AB-Rated Generic Competitors16
2024 CMS Total Public Spend$16.2M
2024 Medicare Part D Spend$13.2M
2024 Medicaid Spend$3.0M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel